AI assistant
NovoCure Ltd — Director's Dealing 2025
Mar 4, 2025
31949_dirs_2025-03-04_a930fb28-4698-4d19-9ff6-ec96d2db68bc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2025-03-03
Reporting Person: Leonard Frank X (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-03 | Ordinary Shares | S | 2527.00 | $18.5363 | Disposed | 143673.00 | Direct |
Footnotes
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: On the transaction date, the reporting person sold 2,527 shares in multiple trades at prices ranging from $18.02 to $18.9918. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.